Nyxoah’s (NYXH) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Nyxoah (NASDAQ:NYXH) in a research note published on Monday,Benzinga reports. They currently have a $11.00 price objective on the stock.

Several other analysts have also weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nyxoah in a research report on Monday, December 29th. Stifel Nicolaus dropped their price target on shares of Nyxoah from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, March 20th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Nyxoah has a consensus rating of “Moderate Buy” and an average price target of $11.25.

Nyxoah Stock Down 0.6%

Shares of NYXH stock opened at $3.17 on Monday. The stock has a market cap of $122.87 million, a P/E ratio of -1.18 and a beta of 1.56. Nyxoah has a one year low of $3.02 and a one year high of $10.98. The stock has a fifty day moving average price of $4.21 and a 200 day moving average price of $4.78. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.25 and a quick ratio of 1.16.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.03). The business had revenue of $6.62 million during the quarter, compared to the consensus estimate of $5.70 million. Nyxoah had a negative net margin of 884.69% and a negative return on equity of 139.18%. Analysts predict that Nyxoah will post -1.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NYXH. Heights Capital Management Inc. acquired a new stake in shares of Nyxoah in the 4th quarter valued at $3,575,000. Shay Capital LLC bought a new stake in shares of Nyxoah in the 2nd quarter worth about $374,000. Kovack Advisors Inc. increased its position in shares of Nyxoah by 67.8% during the 3rd quarter. Kovack Advisors Inc. now owns 97,039 shares of the company’s stock worth $446,000 after purchasing an additional 39,212 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Nyxoah during the 3rd quarter worth about $98,000. Finally, Rossmore Private Capital lifted its holdings in Nyxoah by 12.6% during the 3rd quarter. Rossmore Private Capital now owns 132,746 shares of the company’s stock valued at $616,000 after purchasing an additional 14,806 shares during the last quarter.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.